ArticleOncotarget2016

Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.

Seiya Yokoyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.